The FDA is setting out to streamline international regulations of gene therapies with a pilot program to review applications alongside global regulatory partners, an agency spokesperson told Endpoints News.
The spokesperson said that the program, called the Collaboration on Gene Therapies Global Pilot, is part of the agency’s work toward global regulatory harmonization of these products. The FDA is working with international partners, global regulators and the World Health Organization on these efforts, they said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.